Thermo-Responsive Hydrogel Microcapsule Ocular Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery systems for treating conditions like choroidal neovascularization secondary to age-related macular degeneration require frequent intravitreal injections, which are associated with complications and low patient compliance, and existing systems struggle with controlled release of bioactive agents in the eye.
Innovation Solution
A hydrogel delivery composition comprising degradable microcapsules suspended in a thermo-responsive hydrogel that changes state from liquid-like at room temperature to solid at body temperature, allowing controlled release of treatment agents like anti-VEGF, with components such as PLGA, magnesium hydroxide, and bovine serum albumin for extended duration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If frequent intravitreal injections are administered to deliver anti-VEGF therapeutics, then treatment efficacy is maintained, but patient compliance decreases and complications increase
Solution Approach 1:
The drug is pre-loaded into microcapsules that are suspended in the hydrogel matrix before injection. This preliminary encapsulation action allows the drug to be delivered in a controlled manner over time, eliminating the need for frequent repeat injections while maintaining treatment efficacy
Solution Approach 2:
The hydrogel system provides continuous drug release over an extended period (months) through the degradation of the hydrogel matrix and microcapsules. This continuous action maintains therapeutic drug levels in the eye, replacing the need for discrete frequent injections and improving patient compliance
2Duration of action of moving object
If microcapsules are injected into the eye as independent units, then drug release can be controlled, but microcapsules can become lodged in ocular tissues causing complications
Solution Approach 1:
The microcapsules are merged with the hydrogel matrix to form a unified delivery system. The hydrogel acts as a carrier medium that suspends and distributes the microcapsules evenly, preventing them from becoming lodged in ocular tissues while maintaining controlled drug release capabilities
Solution Approach 2:
The hydrogel serves as an intermediary between the microcapsules and the ocular environment. It provides a biocompatible matrix that facilitates gentle distribution of microcapsules, preventing direct contact and potential damage to sensitive ocular tissues while still allowing controlled drug release
3Ease of operation
If the hydrogel changes state from liquid-like to solid at body temperature, then localized delivery is improved, but control of release rate becomes more difficult
Solution Approach 1:
The release rate is controlled by adjusting parameters of the hydrogel and microcapsule composition, including polymer concentration, cross-linking density, and degradation rate. These parameter changes allow tuning of the release profile to match therapeutic requirements while maintaining the thermo-responsive localization capability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system provides a controlled and extended release of bioactive agents, reducing the frequency of injections, minimizing complications, and maintaining bioactivity for up to six months, thereby improving treatment efficacy and patient compliance.
Implementation Method 1
The hydrogel is thermo-responsive in that it desirably changes its physical state from a liquid-like state at room temperature to a more solid state at body temperature
Implementation Method 2
degradable microcapsules suspended in a degradable thermo-responsive hydrogel
Data Source
AI summary
A hydrogel delivery composition and method, including degradable microcapsules suspended in a degradable thermo-responsive hydrogel. The hydrogel is thermo-responsive at a physiological temperature and changes after application to a more solid state due to body temperatures. The composition includes one or more treatment agents to be released over time as the composition degrades. The composition can be varied to modify the structure and/or release of the treatment agent. The degradable microcapsules include one or more of magnesium hydroxide (Mg(OH)2), bovine serum albumin (BSA), polyethylene glycol (PEG), and sucrose to improve release duration.